The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2023

Filed:

Nov. 07, 2014
Applicant:

University of Virginia Patent Foundation, Charlottesville, VA (US);

Inventors:

Craig L. Slingluff, Jr., Charlottesville, VA (US);

Ileana S. Mauldin, Charlottesville, VA (US);

Assignee:

University of Virginia Patent Foundation, Charlottesville, VA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 37/04 (2006.01); A61K 38/21 (2006.01); A61K 38/08 (2019.01); A61K 31/353 (2006.01); A61K 45/06 (2006.01); A61K 31/7084 (2006.01); A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 38/10 (2006.01); A61K 47/12 (2006.01);
U.S. Cl.
CPC ...
A61K 38/217 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/7084 (2013.01); A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01);
Abstract

Toll-like receptor (TLR) agonists can induce chemokine production. We find that TLR2 and TLR6 are widely expressed on human melanoma cells, and that TLR2/6 agonists (MALP-2 or FSL-1) synergize with interferon-gamma (IFNγ) to induce production of CXCL10 from melanoma cells. Furthermore, melanoma cells and immune cells freshly isolated from surgical specimens also respond to TLR2/6 agonists +IFNγ by upregulating CXCL10 production, compared to treatment with either agent alone. It is also disclosed herein that these compounds are useful in inducing CLXL10 in other types of cancer. Collectively, these data identify a novel synergy of TLR2/6 agonists +IFNγ for inducing CXCL10 production directly from melanoma cells, raising the possibility that intratumoral administration of these agents may improve immune signatures in melanoma and have value in combination with other immune therapies, by supporting T-cell migration into melanoma metastases.


Find Patent Forward Citations

Loading…